Madrigal Pharmaceuticals(MDGL) - 2023 Q2 - Quarterly Report
Madrigal Pharmaceuticals(MDGL)2023-08-08 18:50
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33277 MADRIGAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3508648 (State or other ...